Exact Mass: 457.327745
Exact Mass Matches: 457.327745
Found 335 metabolites which its exact mass value is equals to given mass value 457.327745,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
O-(17-Carboxyheptadecanoyl)carnitine
O-(17-Carboxyheptadecanoyl)carnitine is an acylcarnitine. More specifically, it is an octadecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. O-(17-Carboxyheptadecanoyl)carnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine O-(17-Carboxyheptadecanoyl)carnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
O‐[(4Z)‐Decenoyl]carnitine
O‚Äê[(4Z)‚Äêdecenoyl]carnitine is an acylcarnitine. More specifically, it is an 3-[(4Z)-dec-4-enoyloxy]-4-(trimethylazaniumyl)butanoate ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. O‚Äê[(4Z)‚Äêdecenoyl]carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine O‚Äê[(4Z)‚Äêdecenoyl]carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular O‚Äê[(4Z)‚Äêdecenoyl]carnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
9-HydroxyNonadecanoylcarnitine
C26H51NO5 (457.37670360000004)
9-HydroxyNonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-hydroxynonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-HydroxyNonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-HydroxyNonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
11-HydroxyNonadecanoylcarnitine
C26H51NO5 (457.37670360000004)
11-HydroxyNonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-hydroxynonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-HydroxyNonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-HydroxyNonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
8-[(2R,3S)-3-(8-Hydroxyoctyl)oxiran-2-yl]octanoylcarnitine
8-[(2R,3S)-3-(8-hydroxyoctyl)oxiran-2-yl]octanoylcarnitine is an acylcarnitine. More specifically, it is an 8-[(2R,3S)-3-(8-hydroxyoctyl)oxiran-2-yl]octanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-[(2R,3S)-3-(8-hydroxyoctyl)oxiran-2-yl]octanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 8-[(2R,3S)-3-(8-hydroxyoctyl)oxiran-2-yl]octanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Docosahexaenoyl Glutamic acid
N-docosahexaenoyl glutamic acid belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Glutamic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Glutamic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Glutamic acid is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
(E)-N-(1,3,4,5-tetrahydroxyhexadecan-2-yl)dec-4-enamide
C26H51NO5 (457.37670360000004)
(4E)-3,6-dihydroxy-2-[(2-hydroxydodecanoyl)amino]undec-4-en-1-yl acetate|phlomisamide
(1aR,1bR,2R,3S,3R,3aS,5R,5aS,5bS,6S,7aR,10aS,10bS,10cS)-1a,1b,23a,4,4,5,5,5a,5b,6,7,7a,9,10,10a,10b,10c-octadecahydro-3,5-dihydroxy-3,5a,6,7-tetramethylspiro[8H-benzo[1,2]fluoreno[ 3,4-b]oxirene-8,2(3H)-furo[3,2-b]pyridin]-6(3H)-one
Agelasine (Stereochemistry Of Diterpene Unknown)
C26H40ClN5 (457.29720700000007)
Ala Ile Arg Val
Ala Ile Val Arg
Ala Leu Arg Val
Ala Leu Val Arg
Ala Arg Ile Val
Ala Arg Leu Val
Ala Arg Val Ile
Ala Arg Val Leu
Ala Val Ile Arg
Ala Val Leu Arg
Ala Val Arg Ile
Ala Val Arg Leu
Gly Ile Ile Arg
Gly Ile Leu Arg
Gly Ile Arg Ile
Gly Ile Arg Leu
Gly Leu Ile Arg
Gly Leu Leu Arg
Gly Leu Arg Ile
Gly Leu Arg Leu
Gly Arg Ile Ile
Gly Arg Ile Leu
Gly Arg Leu Ile
Gly Arg Leu Leu
Ile Ala Arg Val
Ile Ala Val Arg
Ile Gly Ile Arg
Ile Gly Leu Arg
Ile Gly Arg Ile
Ile Gly Arg Leu
Ile Ile Gly Arg
Ile Ile Asn Val
Ile Ile Arg Gly
Ile Ile Val Asn
Ile Lys Pro Thr
Ile Lys Thr Pro
Ile Lys Val Val
C22H43N5O5 (457.32640280000004)
Ile Leu Gly Arg
Ile Leu Asn Val
Ile Leu Arg Gly
Ile Leu Val Asn
Ile Asn Ile Val
Ile Asn Leu Val
Ile Asn Val Ile
Ile Asn Val Leu
Ile Pro Lys Thr
Ile Pro Thr Lys
Ile Gln Val Val
Ile Arg Ala Val
Ile Arg Gly Ile
Ile Arg Gly Leu
Ile Arg Ile Gly
Ile Arg Leu Gly
Ile Arg Val Ala
Ile Thr Lys Pro
Ile Thr Pro Lys
Ile Val Ala Arg
Ile Val Ile Asn
Ile Val Lys Val
C22H43N5O5 (457.32640280000004)
Ile Val Leu Asn
Ile Val Asn Ile
Ile Val Asn Leu
Ile Val Gln Val
Ile Val Arg Ala
Ile Val Val Lys
C22H43N5O5 (457.32640280000004)
Ile Val Val Gln
Lys Ile Pro Thr
Lys Ile Thr Pro
Lys Ile Val Val
C22H43N5O5 (457.32640280000004)
Lys Leu Pro Thr
Lys Leu Thr Pro
Lys Leu Val Val
C22H43N5O5 (457.32640280000004)
Lys Pro Ile Thr
Lys Pro Leu Thr
Lys Pro Thr Ile
Lys Pro Thr Leu
Lys Thr Ile Pro
Lys Thr Leu Pro
Lys Thr Pro Ile
Lys Thr Pro Leu
Lys Val Ile Val
C22H43N5O5 (457.32640280000004)
Lys Val Leu Val
C22H43N5O5 (457.32640280000004)
Lys Val Val Ile
C22H43N5O5 (457.32640280000004)
Lys Val Val Leu
C22H43N5O5 (457.32640280000004)
Leu Ala Arg Val
Leu Ala Val Arg
Leu Gly Ile Arg
Leu Gly Leu Arg
Leu Gly Arg Ile
Leu Gly Arg Leu
Leu Ile Gly Arg
Leu Ile Asn Val
Leu Ile Arg Gly
Leu Ile Val Asn
Leu Lys Pro Thr
Leu Lys Thr Pro
Leu Lys Val Val
C22H43N5O5 (457.32640280000004)
Leu Leu Gly Arg
Leu Leu Asn Val
Leu Leu Arg Gly
Leu Leu Val Asn
Leu Asn Ile Val
Leu Asn Leu Val
Leu Asn Val Ile
Leu Asn Val Leu
Leu Pro Lys Thr
Leu Pro Thr Lys
Leu Gln Val Val
Leu Arg Ala Val
Leu Arg Gly Ile
Leu Arg Gly Leu
Leu Arg Ile Gly
Leu Arg Leu Gly
Leu Arg Val Ala
Leu Thr Lys Pro
Leu Thr Pro Lys
Leu Val Ala Arg
Leu Val Ile Asn
Leu Val Lys Val
C22H43N5O5 (457.32640280000004)
Leu Val Leu Asn
Leu Val Asn Ile
Leu Val Asn Leu
Leu Val Gln Val
Leu Val Arg Ala
Leu Val Val Lys
C22H43N5O5 (457.32640280000004)
Leu Val Val Gln
Asn Ile Ile Val
Asn Ile Leu Val
Asn Ile Val Ile
Asn Ile Val Leu
Asn Leu Ile Val
Asn Leu Leu Val
Asn Leu Val Ile
Asn Leu Val Leu
Asn Val Ile Ile
Asn Val Ile Leu
Asn Val Leu Ile
Asn Val Leu Leu
Pro Ile Lys Thr
Pro Ile Thr Lys
Pro Lys Ile Thr
Pro Lys Leu Thr
Pro Lys Thr Ile
Pro Lys Thr Leu
Pro Leu Lys Thr
Pro Leu Thr Lys
Pro Thr Ile Lys
Pro Thr Lys Ile
Pro Thr Lys Leu
Pro Thr Leu Lys
Gln Ile Val Val
Gln Leu Val Val
Gln Val Ile Val
Gln Val Leu Val
Gln Val Val Ile
Gln Val Val Leu
Arg Ala Ile Val
Arg Ala Leu Val
Arg Ala Val Ile
Arg Ala Val Leu
Arg Gly Ile Ile
Arg Gly Ile Leu
Arg Gly Leu Ile
Arg Gly Leu Leu
Arg Ile Ala Val
Arg Ile Gly Ile
Arg Ile Gly Leu
Arg Ile Ile Gly
Arg Ile Leu Gly
Arg Ile Val Ala
Arg Leu Ala Val
Arg Leu Gly Ile
Arg Leu Gly Leu
Arg Leu Ile Gly
Arg Leu Leu Gly
Arg Leu Val Ala
Arg Val Ala Ile
Arg Val Ala Leu
Arg Val Ile Ala
Arg Val Leu Ala
Thr Ile Lys Pro
Thr Ile Pro Lys
Thr Lys Ile Pro
Thr Lys Leu Pro
Thr Lys Pro Ile
Thr Lys Pro Leu
Thr Leu Lys Pro
Thr Leu Pro Lys
Thr Pro Ile Lys
Thr Pro Lys Ile
Thr Pro Lys Leu
Thr Pro Leu Lys
Val Ala Ile Arg
Val Ala Leu Arg
Val Ala Arg Ile
Val Ala Arg Leu
Val Ile Ala Arg
Val Ile Ile Asn
Val Ile Lys Val
C22H43N5O5 (457.32640280000004)
Val Ile Leu Asn
Val Ile Asn Ile
Val Ile Asn Leu
Val Ile Gln Val
Val Ile Arg Ala
Val Ile Val Lys
C22H43N5O5 (457.32640280000004)
Val Ile Val Gln
Val Lys Ile Val
C22H43N5O5 (457.32640280000004)
Val Lys Leu Val
C22H43N5O5 (457.32640280000004)
Val Lys Val Ile
C22H43N5O5 (457.32640280000004)
Val Lys Val Leu
C22H43N5O5 (457.32640280000004)
Val Leu Ala Arg
Val Leu Ile Asn
Val Leu Lys Val
C22H43N5O5 (457.32640280000004)
Val Leu Leu Asn
Val Leu Asn Ile
Val Leu Asn Leu
Val Leu Gln Val
Val Leu Arg Ala
Val Leu Val Lys
C22H43N5O5 (457.32640280000004)
Val Leu Val Gln
Val Asn Ile Ile
Val Asn Ile Leu
Val Asn Leu Ile
Val Asn Leu Leu
Val Gln Ile Val
Val Gln Leu Val
Val Gln Val Ile
Val Gln Val Leu
Val Arg Ala Ile
Val Arg Ala Leu
Val Arg Ile Ala
Val Arg Leu Ala
Val Val Ile Lys
C22H43N5O5 (457.32640280000004)
Val Val Ile Gln
Val Val Lys Ile
C22H43N5O5 (457.32640280000004)
Val Val Lys Leu
C22H43N5O5 (457.32640280000004)
Val Val Leu Lys
C22H43N5O5 (457.32640280000004)
Val Val Leu Gln
Val Val Gln Ile
Val Val Gln Leu
CAR 18:1;O2
disodium N-(1-oxooctadecyl)-L-glutamate
C23H41NNa2O5 (457.27799760000005)
decyl hydrogen sulphate, compound with 1,1,1-nitrilotripropan-2-ol
4-Cyano-4-biphenylyl trans-4-(4-pentylcyclohexyl)-1-cyclohexanecarboxylate
N-(1-Cyclohexylethyl)-N-(1-phenylethyl)dodecahydrodibenzo[d,f][1, 3,2]dioxaphosphepin-6-amine
Nevanimibe hydrochloride
C27H40ClN3O (457.28597400000007)
C471 - Enzyme Inhibitor Nevanimibe hydrochloride (PD-132301 hydrochloride) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe hydrochloride inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe hydrochloride induces cell apoptosis and has the potential for adrenocortical cancer[1].
Octadecanedioic Acid Mono-L-carnitine Ester Chloride
(3beta,9beta)-4alpha-demethyl-4alpha-carboxy-9,19-cyclolanost-3-ol
8-[(2R,3S)-3-(8-Hydroxyoctyl)oxiran-2-yl]octanoylcarnitine
2-[[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]amino]pentanedioic acid
3-[3-[(E)-dec-4-enoyl]oxy-4-(trimethylazaniumyl)butanoyl]oxy-4-(trimethylazaniumyl)butanoate
(12Z,15Z,18Z,21Z,24Z)-2-hydroxytriacontapentaenoate
A hydroxy fatty acid anion that is the conjugate base of (12Z,15Z,18Z,21Z,24Z)-2-hydroxytriacontapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
20-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]icosanoate
19-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxononadecanoate
(19R)-19-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxyicosanoate
(18R)-18-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxononadecanoate
(5Z,8Z,11Z,14Z,17Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]icosa-5,8,11,14,17-pentaenamide
(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide
(4Z,7Z,10Z,13Z)-N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]hexadeca-4,7,10,13-tetraenamide
(4E,8E,12E)-2-(decanoylamino)-3-hydroxytetradeca-4,8,12-triene-1-sulfonic acid
C24H43NO5S (457.2861788000001)
O-(17-carboxyheptadecanoyl)carnitine
An O-acylcarnitine having 17-carboxyheptadecanoyl as the acyl substituent.
N-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-L-glutamic acid
An N-(long-chain-fatty-acyl)-L-glutamic acid in which the acyl group is specified as (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl.
oscr#36(1-)
A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#36, obtained by deprotonation of the carboxy group; major species at pH 7.3.
3-(3-carbamimidamidopropyl)-5-(2-{[(2e,7e)-1-hydroxy-4,8,12-trimethyltrideca-2,7,11-trien-1-ylidene]amino}ethyl)-1-methylimidazol-1-ium
[C26H45N6O]+ (457.36546599999997)
(3s,3ar,4s,6as,11r,14r,15ar)-1,11-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-14-(2-oxopropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione
(3e,5r,6r,7e,9e,12e)-5-hydroxy-14-(4-hydroxy-5,6-dimethoxy-3-methylpyridin-2-yl)-4,6,8,10,12-pentamethyltetradeca-3,7,9,12-tetraen-2-one
(1r,2s,6s,9s,10s,11r,12s,14s,15s,20s,23r,24s)-10,12-dihydroxy-6,10,23-trimethyl-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacos-17-en-20-yl formate
C28H43NO4 (457.31919180000006)
n-[1-(acetyloxy)-3,6-dihydroxyundec-4-en-2-yl]-2-hydroxydodecanimidic acid
2-{[(13z)-1-hydroxydocos-13-en-1-ylidene]amino}benzoic acid
2-(10-hydroxy-3,5,7,9,11,13-hexamethyltetradeca-2,5,7,11-tetraen-1-yl)-5,6-dimethoxy-3-methylpyridin-4-ol
C28H43NO4 (457.31919180000006)
2,3-dimethoxy-6-(10-methoxy-3,7,9,11,13-pentamethyltetradeca-2,5,7,11-tetraen-1-yl)-5-methylpyridin-4-ol
C28H43NO4 (457.31919180000006)
1,11-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-14-(2-oxopropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione
2,3-dimethoxy-6-[(2e,5e,7e,9s,10s,11e)-10-methoxy-3,7,9,11,13-pentamethyltetradeca-2,5,7,11-tetraen-1-yl]-5-methylpyridin-4-ol
C28H43NO4 (457.31919180000006)
(2r)-n-[(2r,3s,4e,6r)-1-(acetyloxy)-3,6-dihydroxyundec-4-en-2-yl]-2-hydroxydodecanimidic acid
2-[(2e,5e,7e,9s,10r,11e)-10-hydroxy-3,5,7,9,11,13-hexamethyltetradeca-2,5,7,11-tetraen-1-yl]-5,6-dimethoxy-3-methylpyridin-4-ol
C28H43NO4 (457.31919180000006)